Neuroprotective therapy for Huntington’s disease: new prospects and challenges

References

• The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Ce1172, 971–983 (1993).
   Google Scholar
• Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 282(5391), 1072–1074 (1998).
   PubMed Web of Science ®Google Scholar
• Squitieri F, Sabbadini G, Mandich P et al Family and molecular data for a fine analysis of age at onset in Huntington's disease. Am. J. Hum. Genet. 95,366–373 (2000).
   Google Scholar
• Rosenblatt A, Ranen N, Nance M, Paulsen J. A physician's guide to the management of Huntington's disease. (2nd Edition), New York: Huntington's Disease Society of America. (1999).
   Google Scholar
• Rosas HD, Koroshetz WJ, Jenkins BG eta] Riluzole therapy in Huntington's disease (HD). May. Disord. 14(2), 326–330 (1999).
   PubMed Web of Science ®Google Scholar
• Paulson HL. Protein Fate in Neurodegenerative Proteinopathies: Polyglutamine Diseases Join the (Mis)Fold. Am.j Hum. Genet. 64,339–345 (1999).
   PubMed Web of Science ®Google Scholar
• •Excellent review of some of the issues surrounding abnormal conformation of mutant huntingtin.
   Google Scholar
• Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc .Natl Acad. Sc]. USA 97(4), 1589–1594 (2000).
   Google Scholar
• Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 287(5459), 1837–1840 (2000).
   PubMed Web of Science ®Google Scholar
• Jana NR, Tanaka M, Wang G, Nukina N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 9(13), 2009–2018 (2000).
   Google Scholar
• Carmichael J, Chatellier J, Woolfson A etal. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl Acad. Sc]. USA 97(17), 9701–9705 (2000).
   Google Scholar
• Sittler A, Lurz R, Lueder G eta]. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10(12), 1307–1315 (2001).
   Google Scholar
• Hackam AS, Yassa AS, Singaraja R eta]. Huntingtin interacting protein 1 induces apoptosis via a novel caspase- dependent death effector domain. J. Biol. Chem. 275(52), 41299–41308 (2000).
   Google Scholar
• Holbert S, Denghien I, Kiechle T eta]. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc. Natl Acad. Sc]. USA 98(4), 1811–1816 (2001).
   Google Scholar
• Rega S, Stiewe T, Chang DI etal. Identification of the Full-Length Huntingtin- Interacting Protein p231HBP/HYPB as a DNA-Binding Factor. Mal. Cell Neurosci. 18(1), 68–79 (2001).
   Google Scholar
• Wellington CL, Singaraja R, Ellerby L et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 275 (26), 19831–19838 (2000).
   Google Scholar
• •Key paper on the possible key role of huntingtin cleavage.
   Google Scholar
• Scherzinger E, Sittler A, Schweiger K etal. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl Acad. Sc]. USA 96(8), 4604–4609 (1999).
   Google Scholar
• DiFiglia M, Sapp E, Chase KO eta]. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334), 1990–1993 (1997).
   PubMed Web of Science ®Google Scholar
• Gutekunst CA, Li SH, Yi H eta]. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. Neurosci. 19(7), 2522–2534 (1999).
   Web of Science ®Google Scholar
• Kuemmerle S, Gutekunst CA, Klein AM eta] Huntington aggregates may not predict neuronal death in Huntingtonis disease. Ann. Nemo'. 46(6), 842–849 (1999).
   PubMed Web of Science ®Google Scholar
• •Important evidence that huntingtin aggregates may not directly cause striatal neuron death.
   Google Scholar
• Kim M, Lee HS, LaForet G eta]. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19(3), 964–973 (1999).
   Google Scholar
• Preisinger E, Jordan BM, Kazantsev A, Housman D. Evidence for a recruitment and sequestration mechanism in Huntingtoris disease. Philos. Trans. 1? Soc. Land. B. Biol Sc]. 354(1386), 1029–1034 (1999).
   Google Scholar
• Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Roc. Natl Acad. Sci USA 96(20), 11404–11409 (1999).
   Google Scholar
• Heiser V, Scherzinger E, Boeddrich A eta]. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl Acad. Sc]. USA 97(12), 6739–6744 (2000).
   Google Scholar
• McCampbell A, Taylor JP, Taye AA et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mal Genet. 9(14), 2197–2202 (2000).
   PubMed Web of Science ®Google Scholar
• •Important paper implicating transcriptional suppression as a mode of neuronal injury.
   Google Scholar
• Boutell JM, Thomas P, Neal JW etal. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 8(9), 1647–1655 (1999).
   Google Scholar
• Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23(9), 387–392 (2000).
   PubMed Web of Science ®Google Scholar
• •Excellent review the of transcriptional dysfunction hypothesis.
   Google Scholar
• Luthi-Carter R, Strand A, Peters NL et al Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mal Genet. 9(9), 1259–1271 (2000).
   PubMed Web of Science ®Google Scholar
• Steffan JS, Kazantsev A, Spasic-Boskovic 0 et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc .Natl Acad. Sci. USA 97(12), 6763–6768 (2000).
   Google Scholar
• Passani LA, Bedford MT, Faber PW et al. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum. Mal Genet. 9(14), 2175–2182 (2000).
   PubMed Web of Science ®Google Scholar
• Nucifora FC, Jr., Sasaki M, Peters ME eta] Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (5512), 2423–2428 (2001).
   Google Scholar
• Boado RJ, Kazantsev A, Apostol BL, Thompson LM, Pardridge WM. Antisense-mediated downregulation of the human huntingtin gene. J. Pharmacol Exp. Ther. 295(1), 239–243 (2000).
   Google Scholar
• Holzmann C, Maueler W, Petersohn D et al. Isolation and characterization of the rat huntingtin promoter. Biochem. 1336 (Pt 1), 227–234 (1998).
   Google Scholar
• Sieradzam KA, Mann DM. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Allp. Neurobial 27 (1), 1–21 (2001).
   Google Scholar
• Zuccato C, Ciammola A, Rigamonti D eta] Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293(5529), 493–498 (2001).
   PubMed Web of Science ®Google Scholar
• •Important paper implicating neurotrophin depletion as a contributor to striatal degeneration.
   Google Scholar
• Canals JM, Checa N, Marco S eta]. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. j Neurosci. 21(1), 117–124 (2001).
   PubMed Web of Science ®Google Scholar
• Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292(5521), 1552–1555 (2001).
   PubMed Web of Science ®Google Scholar
• Salghetti SE, Caudy AA, Chenoweth JG, Tansey WP. Regulation of Transcriptional Activation Domain Function by Ubiquitin. Science 19,19 (2001).
   Google Scholar
• Browne SE, Bowling AC, MacGarvey U eta]. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Newel 41(5), 646–653 (1997).
   Google Scholar
• Schapira AH. Mitochondrial function in Huntington's disease: clues for pathogenesis and prospects for treatment. Ann. Neural. 41(2), 141–142 (1997).
   PubMed Web of Science ®Google Scholar
• •Excellent review of mitochondrial dysfunction in HD.
   Google Scholar
• Ferrante RJ, Andreassen OA, Jenkins BG eta]. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. j Neurosci 20(12), 4389–4397 (2000).
   PubMed Web of Science ®Google Scholar
• •Standard-setting use of HD transgenic mice in preclinical drug testing.
   Google Scholar
• Andreassen OA, Dedeoglu A, Ferrante RJ et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neumbial Dis. 8(3), 479–491 (2001).
   Google Scholar
• Andreassen OA, Ferrante RJ, Huang HM et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann. Neural. 50(1), 112–117 (2001).
   PubMed Web of Science ®Google Scholar
• Murman DL, Giordani B, Mellow AM eta]. Cognitive, behavioral and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology 49(1), 153–161 (1997).
   PubMed Web of Science ®Google Scholar
• Kieburtz K. Antiglutamate therapies in Huntington's disease. j Neural 7iansm. 55(Suppl.), 97–102 (1999).
   Google Scholar
• Kremer B, Clark CM, Almqvist EW eta]. Influence of lamotrigine on progression of early Huntington's disease: a randomized clinical trial. Neurology53 (5), 1000–1011 (1999).
   PubMed Web of Science ®Google Scholar
• Huntington's Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology57,397–404 (2001).
   PubMedGoogle Scholar
• •Results of the landmark CARE-HD study by the HSG.
   Google Scholar
• Sapp E, Kegel KB, Aronin N eta]. Early and progressive accumulation of reactive microglia in the Huntington's disease brain. Neuropathol Exp. Neural 60(2), 161–172 (2001).
   Google Scholar
• Yu Z, Zhou D, Cheng G, Mattson MR Neuroprotective role for the p50 subunit of NF-KB in an experimental model of Huntington's disease. J. Mal Neumsci. 15(1), 31–44 (2000).
   Google Scholar
• Beal ME. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neumsci. 23(7), 298–304 (2000).
   Google Scholar
• Deckel AW Nitric oxide and nitric oxide synthase in Huntington's disease. J. Neumsci. Res. 64(2), 99–107 (2001).
   Google Scholar
• Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95(1), 55–66 (1998).
   PubMed Web of Science ®Google Scholar
• Sanchez I, Xu CJ, Juo P eta]. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22(3), 623–33 (1999).
   Google Scholar
• Li SH, Lam S, Cheng AL, Li XJ. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum. Mal Genet. 9(19), 2859–2867 (2000).
   Google Scholar
• Ona VO, Li M, Vonsattel JP eta]. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399(6733), 263–267 (1999).
   Google Scholar
• Chen M, Ona VO, Li M eta] Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nature Merl 6(7), 797–801 (2000).
   Google Scholar
• Rigamonti D, Bauer JH, De-Fraja C eta] Wild type huntingtin protects from apoptosis upstream of caspase-3. Neumsci. 20(10), 3705–3713 (2000).
   Google Scholar
• Rigamonti D, Sipione S, Goffredo D eta] Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 276(18), 14545–14548 (2001).
   Google Scholar
• •Possible normal function of huntingtin for preventing cell death.
   Google Scholar
• Nance M, Myers R Group TUHDGT. Trends in predictive and prenatal testing for Huntington's disease 1993–1999. Am. J. Hum. Genet. 65(A), 406 (1999).
   Google Scholar
• Quaid K, Morris M. Reluctance to undergo predictive testing: the case of Huntington's disease. Am. Merl Genet 45,41–45 (1993).
   Web of Science ®Google Scholar
• Hayden M. Core predictive testing for Huntington's disease: The calm after the storm. Lancet 356,1944–1945 (2000).
   PubMed Web of Science ®Google Scholar